

VAXIL BIO LTD.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS

For the three- and nine-month periods ended September 30, 2018

The following is a discussion and analysis of the activities, consolidated results of operations and financial condition of Vaxil Bio. Ltd. ("Vaxil", "we", "our", "us", or the "Company") for the three- and nine-month periods ended September 30, 2018, which has been prepared on the basis of information available up until November 29, 2018. This Management's Discussion and Analysis ("MD&A") should be read in conjunction with the Company's interim consolidated financial statements for the three- and nine-month periods ended September 30, 2018, as well as the annual consolidated financial statements for the year ended December 31, 2017, together with the notes thereto.

All monetary amounts are reported in Canadian dollars and in accordance with IFRS unless otherwise noted. This MD&A is dated November 29, 2018.

Forward-Looking Statements

This MD&A (including, without limitation, the sections discussing Vaxil's Financial Conditions and Results of Operations) contains certain forward-looking statements. All statements other than statements of historical fact that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "contemplate", "target", "believe", "plan", "estimate", "expect" and "intend" and statements that an event or result "may", "will", "can", "should", "could" or "might" occur or be achieved and other similar expressions. These statements are based upon certain assumptions and analyses made by management in light of its experience and perception of historical trends, current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. However, whether actual results and developments will conform with management's expectations is subject to a number of risks and uncertainties, including the considerations discussed herein and in other documents filed from time to time by the Company with Canadian security regulatory authorities, general economic, market or business conditions, the opportunities (or lack thereof) that may be presented to and pursued by management, competitive actions by other companies, changes in laws or regulations and other factors, many of which are beyond the Company's control. These factors may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements and there can be no assurance that the actual results or developments anticipated by management will be realized or, even if substantially realized, that they will have the expected results on Vaxil. All of the forward-looking statements made herein are qualified by the foregoing cautionary statements. The Company expressly disclaims any obligation to update or revise any such forward-looking statements.

Business overview and Significant Developments during the period

Corporate Structure

Name and Incorporation

Vaxil Bio Ltd. ("Vaxil" or the "Company") was incorporated under the Business Corporations Act (BC) on July 26, 2006 and is listed on the TSX Venture Exchange under the symbol "VXL". The Company's head office is located at 6th Floor, 4576 Yonge Street, Toronto, Ontario, M2N 6N4, Canada. Vaxil's Israel office is within the Weizmann Science Park, an Israeli biotech hub and adjacent to the famed Weizmann Institute of Science, at Pinchas Sapir Street 3, P.O. Box 4058, Nes Ziona, 74140, Israel. This is also the principal place of business where Vaxil currently hosts its scientific laboratory.

Financial development during 2018 and through to the date of this report

On January 30, 2018, the Company completed a non-brokered private placement financing at a price of \$0.05 per unit, with each unit purchased entitling the investor to one common share and one additional common share purchase warrant (a "Warrant"). Each Warrant is exercisable into one additional common share of Vaxil for a period of 36 months at \$0.10 per common share (share and warrant together referred to as "Unit"). In total, 36,200,000 Units were issued for aggregate gross proceeds of \$1.8 million. The Financing is subject to all necessary regulatory and stock exchange approvals. The securities issued pursuant to the Financing are subject to a four month and one-day hold period expiring May 27, 2018, in accordance with applicable Canadian securities law. In connection with the Financing, Vaxil paid certain finders fees on a portion of funds raised. Aggregate cash commissions of \$57,192 and an aggregate 1,143,849 compensation warrants were paid and issued in connection with the Financing. Certain officers and/or directors of the Company (the "Related Parties") participated in the Financing, which participation constitutes a "related party transaction" as defined under Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101"). Such related party transaction is exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 as neither the fair market value of securities being issued to the related parties nor the consideration being paid by the related parties exceeded 25% of the Company's market capitalization. Vaxil did not file a material change report in respect of the related party transactions less than 21 days prior to the closing of the Financing, which Vaxil deemed reasonable in the circumstances so as to be able to avail itself of the proceeds in an expeditious manner.

On July 31, 2018, the Company issued 2,042,097 shares in order to settle certain liabilities that accrued to related parties in 2017.

On September 4, 2018, the Company granted 4,446,472 stock options to the CEO of the company.

Business of Vaxil

Vaxil Bio Ltd., is an Israeli immuno-oncology biotechnology company researching and developing novel immunotherapies for cancer and other diseases.

The Company's pipeline includes its lead candidate ImMucinTM, a neoantigen-like peptide product, and proprietary antibodies, developed to treat cancer and infectious diseases.

Vaxil's products are derived from its fully owned proprietary platform VaxHitTM, which in effect allows for the identification, isolation, and production of antigen based immunotherapy products.

Vaxil's patented lead product, ImMucinTM is composed of the entire SP domain of the MUC1 tumor associated antigen (TAA) and has successfully completed a Phase I/II clinical trial in 15 cancer patients demonstrating a high safety profile, robust immunity and initial hints of clinical efficacy. ImmucinTM was granted Orphan Drug Status by the FDA and the EMA for MM.

Vaxil's secondary product family is focused on proprietary antibodies, specific to signal peptide domains of targeted tumor markers. To date, Vaxil has isolated SPmAb-2.1 and SPmAb-6, unique in their targeting of the signal peptide of the prominent MUC1 cancer marker. The Company has developed its antibodies with the belief that signal peptide specific targeting could potentially harbour superior or distinct therapeutic and/or diagnostic properties when compared with other antibody products.

Lastly, Vaxil has utilized its core platform algorithm, VaxHitTM in order to research and develop products geared toward infectious diseases. In that regard, Vaxil has developed and patented MTBuVaxTM, a multi-antigenic sub-unit LP vaccine against mycobacterium Tuberculosis (MTb) currently in pre-clinical testing at Vaxil's laboratory in Israel.

During 2018, Vaxil began CMC (Chemistry, Manufacturing, and Controls work to optimize ImmucinTM for future trials. In the third quarter of 2018, we continued this work which we expect to conclude during 2019.

Vaxil has also continued and initiated a number of R&D programs, leveraging its underlying platform technology to explore potential areas of interest, including additional tumor markers and signal peptide antibodies. Vaxil scientists also continue R&D on its MTBuVaxTM Tuberculosis vaccine candidate. During the third quarter of 2018, we initiated an exploratory TB study to assess efficacy.

Vaxil Intellectual Property

Vaxil owns all of its technology and intellectual property outright, with no royalties. Currently, Vaxil maintains a robust IP portfolio including 10 fully issued patents obtained, with an additional eight patents pending.

Capital Expenditures and Divestitures

During the three- and nine-month periods ended September 30, 2018, the Company did not incur any capital expenditures. The Company estimates capital expenditures for the next twelve months is \$50 thousand.

Additional Disclosure for Venture Issuers without Significant Revenues (in Thousands of Canadian Dollars):

	Three months ended		Nine Months ended	
	September 30		September 30	
	2018	2017	2018	2017
Research and development costs, net	\$ 132	\$ 212	\$ 338	\$ 539
General and administration costs	68	123	291	466

Discussion of Operations

The following is a discussion of the results of operations which have been derived from the condensed consolidated interim financial statements of the Company for the three- and nine-month periods ended September 30, 2018 (in Thousands of Canadian Dollars):

	Three months ended		Nine Months ended	
	September 30		September 30	
	2018	2017	2018	2017
Expenses:				
Research and development costs, net	\$ 132	\$ 212	\$ 338	\$ 539
General and administration costs	68	123	291	466
Share based compensation	23	-	23	252
Total Expenses	223	335	652	1,257
Operating Loss	(223)	(335)	(652)	(1,257)
Financial (income) expenses	7	1	(3)	3
	7	1	(3)	3
Net loss for the period	(230)	(336)	(649)	(1,260)
Other Comprehensive Loss				
Foreign currency translation adjustment	(6)	48	(10)	63
Net loss and comprehensive loss for the period	\$ (236)	\$ (288)	\$ (659)	\$ (1,197)

Three-month period ended September 30, 2018, compared to the three-month period ended September 30, 2017

Research and Development costs, net

For the three-month period ended September 30, 2018, research and development costs expenses amounted to \$132 thousand as compared to \$212 thousand for the three-month period ended September 30, 2017. The decrease in research and development costs is as a result of a decrease in salaries and related expenses and a decrease in research and development materials.

General and Administrative Expenses

For the three-month period ended September 30, 2018, general and administrative expenses amounted to \$68 thousand as compared to \$123 thousand for the three-month period ended September 30, 2017. The decrease in general and administrative expenses in 2018 resulted primarily from a decrease in consultants and office rental.

Share based compensation

For the three-month period ended September 30, 2018, share based compensation is \$23 as compared to nil for the three-month period ended September 30, 2017. In September, 2018, the Company granted 4,446,472 stock options to the CEO of the company.

Nine-month period ended September 30, 2018, compared to the nine-month period ended September 30, 2017

Research and Development costs, net

For the nine-month period ended September 30, 2018, research and development costs expenses amounted to \$338 thousand as compared to \$539 thousand for the nine-month period ended September 30, 2017. The decrease in research and development expenses relates primarily to a decrease of salaries and related expenses and a decrease in research and development materials.

General and Administrative Expenses

For the nine-month period ended September 30, 2018, general and administrative expenses amounted to \$291 thousand as compared to \$466 thousand for the nine-month period ended September 30, 2017. The decrease in general and administrative expenses in 2018 resulted primarily from a decrease in consulting, management and directors' fees and office rental as compared to 2017.

Share based compensation

For the nine-month period ended September 30, 2018, share based compensation is nil as compared to \$252 for the nine-month period ended September 30, 2017. In January 2017, the Company issued shares to certain directors and suppliers in lieu of services rendered to the Company.

Net Losses

The Company reported a net loss for the nine-month period ended September 30, 2018 of \$626 thousand as compared to a net loss of \$1,260 for the nine-month period ended September 30, 2017. The decrease in the loss in 2018 is due to reduced research and development costs, and general and administration expenses.

Inflation

During the nine-month period ended September 30, 2018 and 2017, inflation has not had a material impact on our operations.

Litigation

On November 8, 2016, a lawsuit was served in the Tel Aviv Magistrate Court against Vaxil Bio Ltd. (Israel), Vaxil Biotherapeutics Ltd. and the Vaxil Bio Ltd. (Canada) (together: the "Defendants"). The lawsuit was served by the former auditors (the "Plaintiffs") of Vaxil Bio Ltd. (Israel), Vaxil Biotherapeutics Ltd. claiming that they did not receive their full compensation for services provided to the Defendants in the past. Additionally, the Plaintiffs claim to be entitled to a termination fee in respect of future audits because, as they claim, the companies agreed to retain them as auditors for at least three years. The Plaintiffs demanded an amount of NIS 532,695 (\$190 thousand) for the abovementioned services.

The Company is defending these claims and although it is impossible to provide any guarantee as to the outcome of the case it is the Company's assessment, that at this stage, and based on the information known by the Company, that there is more than 50% chance that any claim in excess of NIS 100,000 (\$37 thousand) will be denied.

Summary of Quarterly Results

	Quarter ended			
	30-Sep-18	30-Jun-18	31-Mar-18	31-Dec-17
	Canadians dollars in thousands, except per share data			
Revenues	\$ -	-	-	-
Net loss	\$ (230)	(180)	(239)	(538)
Net loss and comprehensive loss	\$ (236)	(141)	(282)	(569)
Net loss per share	\$ (0.01)	(0.01)	(0.00)	(0.01)

	Quarter ended			
	30-Sep-17	30-Jun-17	31-Mar-17	31-Dec-16
	Canadians dollars in thousands, except per share data			
Revenues	\$ -	-	-	-
Net loss	\$ (336)	(319)	(605)	(634)
Net loss and comprehensive loss	\$ (288)	(367)	(542)	(704)
Net loss per share	\$ (0.01)	(0.01)	(0.01)	(0.01)

Net loss per quarter is a function of the exploration and operational activity during that quarter. The loss per quarter and related loss net loss per share is a function of the level of research and development activity that took place during that quarter. In 2017 and 2018, the losses per quarter relate primarily to research and development costs, including CMC work, advancing our knowledge regarding efficacy of our platform in oncology and infection disease, maintaining our patent portfolio and general and administrative costs.

Liquidity

Liquidity is a measure of a company's ability to meet potential cash requirements. The Company has historically met its capital requirements through the issuance of common shares.

The Company has an accumulated deficit of \$14,888 thousand as of September 30, 2018 (\$14,239 thousand as of December 31, 2017), and the Company had negative cash flows from operations of \$840 thousand for the nine-month period ended September 30, 2018 (negative cash flows of \$901 thousand during the nine-month period ended September 30, 2017). The ability of the Company to continue as a going concern depends upon the ability of the Company to obtain financing to complete development, and upon future profitable operations from the properties or proceeds from their disposition. The Company is an exploration stage company and has not earned any revenues to date.

There can be no assurance that the Company will be able to continue to raise funds, in which case the Company may be unable to meet its obligations. The Company is considering various alternatives with respect to raising additional capital to remedy any future shortfall in capital, but to date has made no specific plans or arrangements. Because of the early stage of the Company's operations, there can be no assurance this capital will be available and if it is not, the Company may be forced to substantially curtail or cease research and development expenditures.

Nine-month period ended September 30, 2018 compared to the nine-month period ended September 30, 2017

During the nine-month period ended September 30, 2018, the Company's overall position of cash and cash equivalents increased by \$882 thousand. This increase in cash and cash equivalents can be attributed to the following activities:

The Company's net cash used in operating activities during the nine-month period ended September 30, 2018 was \$840 thousand as compared to \$901 thousand for the nine-month period ended September 30, 2017. The decrease was due primarily to the decrease in net loss for the period.

Cash flows from financing activities for the nine-month period ended September 30, 2018 was \$1,722 as compared to \$22 used during the nine-month period ended September 30, 2017. In 2018, the Company completed a private placement and raised \$1,745 net of share issuance expenses.

Capital Resources

As of September 30, 2018, the Company's cash and cash equivalents were \$1,040 thousand (December 31, 2017 - \$169 thousand). The majority of this balance is being held in Canadian Dollars. Our working capital at September 30, 2018 was positive \$705 thousand as compared to negative working capital of \$605 at December 31, 2017. The Company increased its working capital as a result of a private placement in January 2018 in which we raised \$1.8 million (gross).

Commitments

The Company has an agreement for the lease of the offices in Israel for a period ending in February 2019. The total future minimum lease payments under the operating lease is \$25 thousand.

Disclosure of Outstanding Share Data

As of the date of this report, the Company has 88,929,447 ordinary shares outstanding, of 52,172,025 warrants outstanding and 7,171,472 options granted. Each warrant and option entitles the right of the holder thereof to acquire one ordinary share.

Management of Capital

The Company is an early-stage biotechnology research and development company and currently does not generate significant cash flows from operations. The Company's primary source of funds comes from the issuance of share capital. The Company does not use other sources of financing that require fixed payments of interest and principal and is not subject to any externally imposed capital requirements.

The Company defines its capital as share capital plus warrants. To effectively manage the Company's capital requirements, the Company has a planning and budgeting process in place to ensure that adequate funds are available to meet its strategic goals. The Company monitors actual expenses to budget to manage its costs and commitments.

The Company's capital management objective is to maximize investment returns to its equity-linked stakeholders within the context of relevant opportunities and risks associated with the Company's operations. Achieving this objective requires management to consider the underlying nature of research and development activities, the availability of capital, the cost of various capital alternatives and other factors. Establishing and adjusting capital requirements is a continuous management process.

Although the Company has been successful at raising funds in the past through the issuance of share capital, there can be no assurance that future financings will be successful.

Off-Balance Sheet arrangements

See "Commitments" above.

Transactions with Related Parties

The following are the expenses incurred with related parties for the nine-months ended September 30, 2018 and 2017 and the balances owing as of September 30, 2018 and 2017:

For the nine-months ended September 30, 2018 (in thousands of Canadian Dollars)

	Directors Fees	Consulting Fees	Share based awards	Option based awards	Total	Amounts owing at September 30, 2018
David Goren, Director and CEO	\$ -	\$ 9	\$ -	\$ -	\$ 9	\$ 9
Gadi Levin, Director and CFO	-	44	-	-	44	5
Isaac Maresky, Director	-	110	-	-	110	9
Total	\$ -	\$ 162	\$ -	\$ -	\$ 162	\$ 23

For the nine-months ended September 30, 2017 (in thousands of Canadian Dollars)

	Directors Fees	Consulting Fees	Share based awards	Option based awards	Total	Amounts owing at September 30, 2017
Gadi Levin, Director and CFO	\$ -	\$ 32	\$ -	\$ -	\$ 32	\$ 4
Isaac Maresky, Director	-	84	-	-	84	8
Saeid Babaei, Director	-	23	-	-	23	3
Total	\$ -	\$ 139	\$ -	\$ -	\$ 139	\$ 15

Critical Accounting Policies and Estimates

Our results of operation and financial condition are based on our consolidated financial statements, which are presented in accordance with IFRS. Certain accounting principles require us to make certain estimates, judgments and assumptions. We believe that the estimates, judgments and assumptions upon which we rely are reasonable based upon information available to us at that time. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements, as well as the reported amounts of revenues and expenses during the periods presented. To the extent there are material differences between these estimates, judgments or assumptions and actual results, our financial statements will be affected. The significant accounting policies and estimates that we believe are the most critical to aid in fully understanding and evaluating our reported financial results include the following:

- Determination of functional currency

The key assumptions made in the financial statements concerning uncertainties at the end of the reporting period and the critical estimates computed by the Company that may result in a material adjustment to the carrying amounts of assets and liabilities within the next financial year.

Determination of functional currency

These condensed consolidated interim financial statements are presented in Canadian dollars. The functional currency of Vaxil is the Canadian dollar. The functional currency of Vaxil Israel is the New Israeli Shekel (“NIS”).

Translation gains or losses resulting from the translation of the financial statements of Vaxil Israel into Canadian dollars are recorded in other comprehensive (loss) income.

Within each entity, transactions in currencies other than the functional currency (“foreign currencies”) are translated to the functional currency at the rate of exchange prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated to the functional currency at the end of each reporting period at the period-end exchange rate. Exchange gains and losses on the settlement of transactions and the translation of monetary assets and liabilities to the functional currency are recorded in profit or loss.

Disclosure Controls and Procedures and Internal Controls over Financial Reporting

There were no changes to the Company’s internal controls over financial reporting during the nine-month period ended September 30, 2018, which have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

As of September 30, 2018, the Company evaluated its disclosure controls and procedures and internal control over financial reporting, as defined by the Canadian Securities Administrators. These evaluations were carried out under the supervision of and with the participation of management, including the Company’s chief financial officer. Based on these evaluations, the chief financial officer concluded that the design of these disclosure controls and procedures and internal control over financial reporting were effective.

Financial Instruments and Other Instruments

The Company’s financial instruments have been designated as follows:

<u>Financial assets and liabilities</u>	<u>Classification</u>
Cash and cash equivalents	Loans and receivables
Other receivables	Loans and receivables
Account payable	Other financial liabilities
Other payables and accrued liabilities	Other financial liabilities

The carrying values of cash and cash equivalents, restricted deposits, other receivables, trade payables and accounts payable and accrued liabilities approximate their fair values due to the short-term maturity of these financial instruments.

Risks and Uncertainties

Credit risk

The Company manages credit risk, in respect of cash and cash equivalents and restricted deposits, by holding them at major Canadian and Israeli financial institutions in accordance with the Company’s investment policy. The Company places its cash and cash equivalents with high credit quality Israeli and Canadian financial institutions. Concentration of credit risk exists with respect to the Company’s cash and cash equivalents and other receivables. The Company’s exposure as at September 30, 2018 and December 31, 2017 was \$1,074 thousand and \$192 thousand respectively, which consisted of \$1,040 thousand (December 31, 2017 - \$169 thousand) in cash held in bank accounts, and \$34 thousand (December 31, 2017 - \$23 thousand) in amounts receivable and prepaid expenses. None of the Company’s amounts receivable are overdue as at September 30, 2018.

Liquidity risk

Liquidity risk is the risk that the Company will encounter difficulty in obtaining funds to meet current obligations and future commitments. The Company’s approach to managing liquidity risk is to forecast cash requirements to provide reasonable assurance that it will have sufficient funds to meet its liabilities when due. As of September 30, 2018, the Company had cash and cash equivalents of \$1,040 thousand and amounts receivable and prepaid expenses of \$34 thousand to settle other payables in the amount of \$345 thousand.

Market risk

Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk is comprised of two types of risk: interest rate risk, and foreign currency risk.

(i) Interest rate risk

The Company is not exposed to significant interest rate risk due to the short-term maturity of its cash equivalents.

(ii) Foreign currency risk

The Company is exposed to financial risk related to the fluctuation of foreign exchange rates. The Company operates in Israel and most of the Company's expenditures are currently incurred in NIS. However, the Company also has expenditures in US Dollars and Canadian Dollars. The Company has not hedged its exposure to currency fluctuations. An increase or decrease of 5% of the NIS or the US Dollar relative to the Canadian dollar would not have a significant effect on the Company.

Development Stage Company

Vaxil has only a limited history upon which one can evaluate its business and prospects as its technologies are still at an early stage of development and thus Vaxil has limited experience and have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biopharmaceutical area. Vaxil has not begun to market or generate revenues from the commercialization of any products related to human health. The likelihood of the success of the Company must be considered in light of the risks inherent in, and the difficulties, costs and complications associated with the early growth stages of a business enterprise, as well as with the development and marketing of new products.

Future Capital Needs

The Company may not be able to fully implement and execute its business strategy without additional financing. There can be no assurance that such additional financing will be available, and if available, there can be no assurance that the cost of obtaining such financing will be on favourable or reasonable commercial terms or that it will not result in substantial dilution to its shareholders. If additional funds are raised through the issuance of equity or equity-linked debt securities, the percentage ownership in Vaxil of the shareholders will be reduced, and such securities may have rights, preferences, or privileges senior to or equal to those of the Company's shares held by the current shareholders, or any other securities outstanding on the date hereof.

If adequate funds are not available to satisfy ongoing capital requirements, the Company may be required to curtail its operations significantly or to obtain funds, if available, through arrangements with strategic partners or others that may require the Company to relinquish material rights to certain technologies or potential markets. There is no certainty that financing will be available in amounts or on acceptable terms, if at all.

Any failure to raise additional funds on favorable terms is likely to have a material adverse effect on the Company's liquidity and financial condition.

Dependence on Key Personnel

The Company's future success depends on its ability to retain key employees and attract, train, retain and successfully integrate new talent into its management team. Vaxil is dependent on the services of its senior management team. The loss of any of the members of the Company's senior management team could have a material adverse effect on the Company's results of operations, business and prospects. The Company's future success also depends, to a significant extent, on its ability to attract and retain talented personnel. Recruiting and retaining talented personnel, particularly those with the expertise required for the Company's business is vital to the Company's success and may prove difficult.

Changes in Technology and Industry Standards

The pharmaceutical and biotechnology drug development industry is susceptible to technological advances and the introduction of new technologies. Further, this industry is also subject to changing industry standards, market trends and customer preferences and to competitive pressures, which can, among other things, necessitate revisions in pricing strategies, price reductions and reduced profit margins. The success of the Company will depend, in part, on its ability to secure technological superiority in its products and operations and maintain such superiority in the face of new technologies. No assurance can be given that further modification of product offerings of Vaxil will not be required in order to meet demands or to make changes necessitated by developments made by competitors that might render services and operations of the Company less competitive. The future success of the Company will be influenced by its ability to continue to adapt its products. Although Vaxil has committed resources to research and develop its products, there can be no assurance that these efforts will be successful.

Applicability of Patents and Proprietary Technology

Competitors may have filed patent applications, or hold issued patents, relating to products or processes competitive with those Vaxil has developed or will in future develop. The Company's patent applications for a product may not be approved or approved as desired. The patents of the Company's competitors may impair its ability to do business in a particular area. Others may independently develop similar products or duplicate any of the Company's unpatented products or technologies. The Company's success will depend, in part, on its ability in the future to obtain patents, protect trade secrets and other proprietary information and operate without infringing the proprietary rights of others. Patent protection is uncertain and involves many complex legal, scientific and technical questions. The degree of legal protection afforded under patents is unclear. As a result, the scope of patents issued to Vaxil or their partners may not successfully prevent third parties from developing similar or competitive products.

Vaxil has and will continue to enter into confidentiality agreements with its employees, suppliers and vendors. However, these confidentiality agreements may be breached, and the Company may not have adequate remedies for such breaches. Others may independently develop substantially equivalent proprietary information without infringing upon any proprietary technology belonging to the Company. Third parties may otherwise gain access to the Company's proprietary information and adopt it in a competitive manner.

In addition, the coverage claimed in a patent application can be significantly reduced before a patent is issued. Also, Vaxil faces the following intellectual property risks: (i) some or all patent applications may not result in the issuance of a patent; (ii) patents issued may not provide the holder with any competitive advantages; (iii) patents could be challenged by third parties; (iv) the patents of others could impede our ability to do business; (v) competitors may find ways to design around our patented products; and (vi) competitors could independently develop products which duplicate our products.

Patent Litigation

A number of industry competitors and institutions have developed technologies, filed patent applications or received patents on various technologies that may be related to or affect our business. Claims by these companies that Vaxil infringes their proprietary technology may result in liability for damages or may delay the development and commercialization efforts for the Company's products. Such conflict could limit the scope of the patents, if any, that the Company may be able to obtain or result in the denial of its patent applications. In addition, if patents that cover the Company's activities are issued to other companies, there can be no assurance that Vaxil would be able to obtain licenses to these patents at a reasonable cost or be able to develop or obtain alternative technology. If the Company does not obtain such licenses, it could encounter delays in the introduction of products, or could find that the development, manufacture or sale of products requiring such licenses could be prohibited. In the pharmaceutical industry, it is not uncommon for competitors to advance such claims for strategic purposes. Furthermore, there can be no assurance that patent or other litigation will not arise in connection with any of the Company's or future products or product candidates. Patent litigation, with or without merit, is time-consuming and costly and may significantly impact the Company's financial condition and results of operations, even if the Company prevails. In addition, the Company could incur substantial costs in defending suits brought against it on patents it might infringe or in filing suits against others to have such patents declared invalid.

####